文献速递骨软组织肉瘤与黑色素瘤

化疗对四肢与躯干壁软组织肉瘤患者生存的影响:重新审视EORTC-STBSG 62931随机试验结果

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
PubMed 文献 · Eur J Cancer · 2019-01-25

该研究在EORTC-STBSG 62931随机对照试验中,用列线图Sarculator计算290例四肢与躯干壁软组织肉瘤患者的10年预测总生存概率并分组。结果显示,在低预测总生存组中,辅助多柔比星联合异环磷酰胺较观察减半复发和死亡风险,中、高预测总生存组未检测到疗效。

要点

  • 在低预测总生存组中,辅助化疗使复发风险减半(HR=0.46,95%CI 0.24-0.89)。
  • 在低预测总生存组中,辅助化疗使死亡风险减半(HR=0.46,95%CI 0.23-0.94)。
  • 中、高预测总生存组未检测到辅助化疗的疗效。

核心结论

  • EORTC-STBSG 62931随机对照试验中,四肢与躯干壁软组织肉瘤且预测总生存概率低的患者(高危患者),接受辅助化疗后结局更好。
  • 该结果可能有助于调和软组织肉瘤辅助/新辅助化疗临床研究结果不一致的问题。

研究设计与样本

  • 对EORTC-STBSG 62931随机对照试验中四肢与躯干壁软组织肉瘤患者进行分析(N=290/351)。
  • 使用预后列线图Sarculator计算10年预测总生存概率(pr-OS)。
  • 按预测总生存概率分为三组:高(pr-OS>66%)、中(51<pr-OS≤66%)、低(pr-OS≤51%)。
  • 比较辅助多柔比星联合异环磷酰胺(Adj)与观察(Obs)的总生存和无病生存。

主要发现

  • 列线图预测总生存概率分布分散(中位数72%,四分位距57-83%),对总生存和无病生存有预后价值(log-rank检验:P<0.001)。
  • 高预测总生存组170例(58.6%,观察90例/辅助80例),中预测总生存组68例(23.5%,观察34例/辅助34例),低预测总生存组52例(17.9%,观察24例/辅助28例)。
  • 低预测总生存组中,辅助化疗使复发风险减半(HR=0.46,95%CI 0.24-0.89),死亡风险减半(HR=0.46,95%CI 0.23-0.94)。
  • 中、高预测总生存组未检测到辅助化疗的疗效。
  • 将预测总生存概率<60%的研究参与者合并(N=80,27.6%,观察39例/辅助41例),检测到显著的无病生存获益(HR=0.49,95%CI 0.28-0.85)和总生存获益(HR=0.50,95%CI 0.30-0.90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study was aimed at determining whether patients with high-risk soft tissue sarcoma (STS), as identified using the nomogram Sarculator, benefitted from adjuvant chemotherapy in the EORTC-STBSG 62931 randomised controlled trial (RCT), which failed to detect an impact for adjuvant doxorubicin plus ifosfamide (Adj) over observation (Obs). METHODS: Patients with extremity and trunk wall STS in the EORTC-STBSG 62931 RCT were analysed (N = 290/351). Ten-year predicted probability of overall survival (pr-OS) was calculated using the prognostic nomogram Sarculator. Patients were grouped into three categories of predicted pr-OS: high (pr-OS>66%), intermediate (51<pr-OS≤66) and low (pr-OS≤51%). OS and disease-free survival (DFS) were calculated. RESULTS: Nomogram pr-OS was dispersed (median 72%, interquartile range 57-83%) and had prognostic value for OS and DFS (log-rank test: P < 0.001). One hundred seventy, 68 and 52 patients had high (58.6%, 90 Obs/80 Adj), intermediate (23.5%, 34 Obs/34 Adj) and low pr-OS (17.9%, 24 Obs/28 Adj), respectively. Adjuvant chemotherapy halved the risk of recurrence (hazard ratio [HR] = 0.46, 95% confidence interval [CI] 0.24-0.89) and death (HR = 0.46, 95% CI 0.23-0.94) in the low pr-OS category, while no effect was detected in intermediate and high pr-OS categories. To strengthen these findings, study participants with pr-OS<60% were combined (N = 80, 27.6%, 39 Obs/41 Adj), and a significant DFS (HR = 0.49, 95% CI 0.28-0.85) and OS (HR = 0.50, 95% CI 0.30-0.90) benefit was detected. CONCLUSION: Patients of the EORTC-STBSG 62931 RCT with extremity and trunk wall STS and a low predicted pr-OS (high-risk patients) had better outcomes when treated with adjuvant chemotherapy. This may help reconcile the disparate results of clinical studies on adjuvant/neoadjuvant chemotherapy in STS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pasquali S, Pizzamiglio S, Touati N, et al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019. PMID: 30690293. doi:10.1016/j.ejca.2018.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。